NCT03015922Unknown1 期
VIRel: Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma - A Phase I Study to Assess the Safety and Tolerability of REOLYSIN® (Pelareorep) in Combination With Lenalidomide or Pomalidomide
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 4
- 试验地点
- 2
- 主要终点
- Dose-limiting toxicities
研究概览
简要总结
This study will recruit patients currently receiving either lenalidomide or pomalidomide whose disease is relapsing. This is a dose escalation study and the aim is to determine the maximum tolerated dose (MTD) of REOLYSIN® that can be given in combination with lenalidomide or pomalidomide. The study will also investigate the safety, side effects and effectiveness of this treatment combination. Pomalidomide and lenalidomide will be evaluated separately as two separate groups.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with symptomatic multiple myeloma (according to IMWG 2014 criteria)
- •Evaluable disease by modified IMWG criteria (i.e. by abnormal serum M protein, urinary M protein or serum free light chain assays)
- •Currently receiving either lenalidomide or pomalidomide therapy, alone or in combination with other myeloma therapy, with evidence of serological or clinical disease progression as defined by IMWG criteria (2011)
- •Life expectancy of ≥ 3 months
- •ECOG performance status of ≤2
- •Required laboratory values within 14 days prior to dose allocation:
- •Absolute neutrophil count ≥ 1.0 x10^9 /L. (growth factor support is not permitted)
- •Platelet count ≥ 70 x 10^9/L. (platelet support is not permitted; platelets < 70 but ≥ 25 acceptable if bone marrow is > 50% infiltrated by MM)
- •Haemoglobin ≥ 8 g/dL. Blood support is permitted
- •Serum bilirubin ≤ 2 x upper limit of normal (ULN)
- •ALT or AST ≤ 2.5 x ULN
- •Serum creatinine ≤ 2 x ULN
- •Corrected calcium ≤ 2.8 mmol/l
- •Negative HIV and viral (B and C) hepatitis test result within 14 days prior to dose allocation
- •Able to give informed consent and willing to follow trial protocol
- •Aged 18 years or over
- •All participants must agree to follow the Celgene Pregnancy Prevention Programme (PPP) and participate in the counselling associated with this:
- •Females of childbearing potential (FCBP) must agree to utilise two reliable forms of contraception simultaneously or practice complete abstinence for at least for 28 days prior to starting trial treatment, during the trial and for at least 28 days after trial treatment discontinuation, and even in case of dose interruption, and must agree to Celgene PPP pregnancy testing during this timeframe
- •Females must agree to abstain from breastfeeding during trial participation and 28 days after trial drug discontinuation
- •Males must agree to use a latex condom during any sexual contact with FCBP (or must practice complete abstinence) during the trial, including during dose interruptions and for 28 days following discontinuation from this trial even if he has undergone a successful vasectomy
- •Males must also agree to refrain from donating semen or sperm while on pomalidomide including during any dose interruptions and for 28 days after discontinuation from this trial
- •All participants must agree to refrain from donating blood while on trial drug including during dose interruptions and for 28 days after discontinuation from this trial
排除标准
- •Non-secretory multiple myeloma
- •Pregnant (positive pregnancy test) in line with the Celgene Pregnancy Prevention Programme or breast feeding
- •Previous anti-tumour therapies including experimental agents, other than lenalidomide or pomalidomide, within 28 days of the start of protocol treatment. Steroid therapy is permitted, but must be stopped 48 hours prior to cycle 1 day 1
- •Concurrent or previous malignancies (<12 months post end of treatment) at other sites, with the exception of appropriately treated localised epithelial skin or cervical cancer, or incidental histologic findings of prostate cancer (TNM stage T1a or 1b). Participants with histories (≥12 months) of other tumours, in remission and not currently on therapy, may be entered
- •System corticosteroid therapy for comorbidities (i.e. medical conditions other than multiple myeloma) that cannot be stopped for the duration of the trial. Topical corticosteroid therapy is not an exclusion criterion.
- •Any history of known hypersensitivity to any of the trial medications or excipients
- •Active symptomatic fungal, bacterial, and/or viral infection
- •Poorly controlled or serious medical or psychiatric illness that, in the Investigator's opinion, is likely to interfere with participation and/or compliance in this clinical trial
- •Patients with significant cardiovascular disease (e.g. history of congestive heart failure requiring therapy (≥ NYHA Class III), presence of severe valvular heart disease, presence of an atrial or ventricular arrhythmia requiring treatment, uncontrolled hypertension, or history of QTc abnormalities)
- •Radiotherapy or major surgery within 4 weeks prior to registration
- •Greater than or equal to grade 2 neuropathy, with or without pain
研究组 & 干预措施
Lenalidomide or pomalidomide, plus REOLYSIN
Experimental
Lenalidomide capsules, oral, maximum 10mg daily on days 1-21 of 28-day cycles. OR Pomalidomide capsules, oral, maximum 1mg daily on days 1-21 of 28-day cycles.
Plus (all patients):
REOLYSIN® , intravenous infusion, maximum 3x10^10 TCID50 on days 1, 8, 15 and 22 of 28-day cycles.
干预措施: REOLYSIN (Biological)
Lenalidomide or pomalidomide, plus REOLYSIN
Experimental
Lenalidomide capsules, oral, maximum 10mg daily on days 1-21 of 28-day cycles. OR Pomalidomide capsules, oral, maximum 1mg daily on days 1-21 of 28-day cycles.
Plus (all patients):
REOLYSIN® , intravenous infusion, maximum 3x10^10 TCID50 on days 1, 8, 15 and 22 of 28-day cycles.
干预措施: Lenalidomide or Pomalidomide (Drug)
结局指标
主要结局
Dose-limiting toxicities
时间窗: After cycle 1 (28 days) of treatment. Assessed in real-time for each patient to inform dose escalation decisions.
Dose-limiting toxicities (DLTs), within the first cycle (until cycle 2, day 1), in order to establish the Maximum Tolerated Dose (MTD) of REOLYSIN® in combination with lenalidomide or pomalidomide, in two separate groups of participants.
次要结局
- Safety profile of REOLYSIN® and lenalidomide(Until 28 days after the last dose of trial treatment for each patient. Assessed up to 27 months.)
- Safety profile of REOLYSIN® and pomalidomide(Until 28 days after the last dose of trial treatment for each patient. Assessed up to 27 months.)
- Toxicity profile of REOLYSIN® and lenalidomide(Until 28 days after the last dose of trial treatment fior each patient. Assessed up to 27 months.)
- Overall survival(Calculated for each patient from the date of registration to death. Assessed up to 27 months.)
- Toxicity profile of REOLYSIN® and pomalidomide(Until 28 days after the last dose of trial treatment fior each patient. Assessed up to 27 months.)
- Response rate (stable disease or better) after 6 cycles of therapy(Data will be collected from each patient after they have received 6 cycles of therapy, if this stage is reached. 6 cycles are expected to take 24 weeks to complete.)
- Maximum response within 6 cycles of therapy(Assessed for each patient after they have received 6 cycles of treatment. 6 cycles are expected to take 24 weeks to complete.)
- Progression-free survival(Calculated for each patient from the date of registration up to first documented evidence of disease progression or death. Assessed up to 27 months.)
- Maximum response overall(Assessed for each patient after they have completed treatment on the trial. Assessed up to 27 months.)
- Time to maximum response(Assessed for each patient after they have completed treatment on the trial. Assessed up to 27 months.)
研究者
Gordon Cook
Consultant Haematologist
The Leeds Teaching Hospitals NHS Trust
研究点 (2)
Loading locations...
相似试验
终止
2 期
Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) PatientsPeripheral T-cell LymphomaNCT01036399University of Bologna9
终止
2 期
Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's DiseaseHodgkin's DiseaseB-Cell LymphomaNCT00209014Emory University2
已完成
2 期
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic AmyloidosisMultiple Myeloma and Plasma Cell NeoplasmNCT00564889Mayo Clinic35
终止
4 期
Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B PatientsChronic Hepatitis BNCT00798460Inje University30
已完成
不适用
Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple MyelomaMultiple MyelomaNCT00135187University of Michigan Rogel Cancer Center30